aibioBy aibio.space
Oncolytics has about two months of cash at its average burn
Cash of $4.1 million covers about two months at average burn, and the company's own going concern language points the same way.
ONCY Negative view Cash covers about two months at average burn, quarterly burn is higher than a year earlier, and the company says its cash falls short of twelve months.
Oncolytics Biotech is a clinical-stage company developing pelareorep, an intravenous immunotherapy for gastrointestinal cancers, according to its annual report. At June 30, 2026 it held $4.1 million in cash and cash equivalents. At the average quarterly operating outflow of $6.1 million, that cash lasts about two months. The company says its cash cannot fund planned operations for at least twelve months. We think investors should start with that gap.
What the company does and where it is
Pelareorep is a proprietary form of reovirus, a virus the annual report describes as common in environmental waters. The company says it replicates in RAS-mutated tumors and changes the tumor environment, so that chemotherapies, checkpoint inhibitors and other immuno-oncology treatments may work better. Its primary focus is gastrointestinal cancers. The filing names metastatic colorectal cancer, second-line or later anal cancer and metastatic pancreatic cancer as areas it is exploring for registrational programs.
The company launched a randomized Phase 2 study in second-line colorectal cancer in 2026 and expects preliminary data by year-end. The FDA granted Fast Track Designation for that indication in 2026. The annual report said the company expected to ask the FDA in April 2026 to agree to a single-arm registrational study in anal cancer of under 100 patients. The 10-Q reports what happened. The company met the FDA in a Type C meeting in mid-April and aligned on a study that is now expected to be a randomized controlled trial of pelareorep with a checkpoint inhibitor against a control arm. The FDA granted Fast Track designation in July 2026. The protocol is still being finalized, and the filing gives no size or cost. We think a randomized trial with a control arm is larger, slower and more expensive than the single-arm study the company described in March.
Cash and burn
The runway arithmetic is short. Cash of $4.1 million divided by $6.1 million a quarter is 0.7 quarters, or about two months. The $6.1 million is the average of the last four quarters. The last two quarters averaged $7.7 million, which would make the runway shorter still.
Cash fell from $11.1 million at December 2024 to $5.2 million at December 2025. It rose slightly to $5.5 million in March 2026, then fell to $4.1 million at June 2026. The 10-Q shows how the company covered the March quarter, when operating cash use was $7.3 million. It issued stock under an at-the-market agreement with BTIG that allows up to $50 million: 7,446,574 shares for $7.9 million gross at an average of $1.06 in that quarter, and 7,859,359 more in the June quarter for $6.8 million net. Shares outstanding rose from 108,021,271 at December 31, 2025 to 127,510,505 on August 10, 2026, about 18% in under eight months.
Burn is the bigger problem. The quarter ended June 2026 used $8.1 million of operating cash, higher than the $4.1 million used in the June 2025 quarter. The March 2026 quarter used $7.3 million, against $4.7 million a year before. Both recent quarters are above the four-quarter average, so our arithmetic is the generous case.
What management says about its cash
The company's wording is more careful than our arithmetic. Its latest 10-Q says existing cash, even with capital it may raise under its equity distribution arrangements, is sufficient for near-term operating milestones. It also says that cash is not sufficient to fund planned operations for at least twelve months. The text we reviewed gives no month count, so we cannot test that claim directly.
We think the difference comes from those equity distribution arrangements. Our arithmetic counts cash only. From July 1 to August 10, 2026 the company issued 2,322,984 shares at an average of $0.81, for $1.9 million gross. That price is below the $1.00 Nasdaq minimum bid, and $1.9 million over six weeks is less than a quarter of the June quarter's operating outflow of $8.1 million. A claim that leans on money not yet raised is weaker than it sounds.
The going concern language is firmer. The 10-Q says the statements assume the company will continue as a going concern, and that these conditions raise substantial doubt about that. This is not new. In May 2025, in its first-quarter statements, the company flagged going concern doubt and said its cash could fund operations through the third quarter of 2025. That report was in Canadian dollars. The company has paid for operations with at-the-market stock issuance since.
Where the money goes
Research and development expense was $4.3 million in the June 2026 quarter, against $1.9 million a year earlier. The 10-Q points to start-up costs for the second-line colorectal study and to personnel costs, including non-cash stock compensation. General and administrative expense was $5,117 thousand in the quarter, against $2,735 thousand a year earlier. The filing lists public company costs first, including investor relations and legal and tax fees tied to the Domestication, the move of the company's legal home from Alberta to Nevada.
We think the G&A rise deserves a question. Part of the public company cost is non-cash: the filing cites $603 thousand of stock compensation for consulting services in the quarter. Even so, with $4.1 million in cash, investor relations and Domestication fees compete with trial spending.
The bull case
The bull case rests on the company's own data and on FDA interest. The company reports a 33% objective response rate for pelareorep-based therapy in second-line colorectal cancer. The comparison figure of about 10% comes from historical studies of standard care, not from a control arm in the same trial, so it is not a controlled result. The randomized REO 033 study, launched in 2026, is the first real test. In third-line anal cancer, four of 14 evaluable patients responded to pelareorep and atezolizumab, with a median duration of response of about 17 months. The FDA has granted Fast Track in both colorectal and anal cancer in 2026, which is a sign of regulatory interest and not of efficacy.
The bear case
The bear case is the cash, and the company's own warning about it. Cash fell from $11.1 million at December 2024 to $4.1 million at June 2026, while operating cash use rose to $8.1 million in the June 2026 quarter. The going concern warning now runs from the 2025 statements into the latest 10-Q.
The clinical evidence is thin on independent numbers. The third-line anal cancer figure rests on four of 14 evaluable patients, and the company reports it itself. The colorectal and anal cancer results are single-arm cohorts compared with history. The one randomized trial the annual report cites, IND.213 in breast cancer with 74 patients, is in a different disease from the gastrointestinal cancers the company now says are its focus. The design the FDA aligned on in anal cancer is a controlled trial, and a randomized colorectal study, a first-line pancreatic cohort and RAS work are running or planned at the same time. The filings give no budget for any of them.
Our view
This is our opinion, not investment advice. We think the bear case is stronger. The bull case rests on response rates the company reports itself, without independent confirmation in the filings we reviewed. The bear case rests on the balance sheet: $4.1 million of cash, recent quarterly operating cash use above $6.1 million, and a going concern warning that has lasted into the latest filing. We think the balance sheet deserves more weight until the company shows how it will fund the next study.
What to watch, and what would change our mind
Three things matter most. First, the terms and size of any sales under the equity distribution arrangements, since the near-term claim depends on them. Second, the final size and cost of the randomized anal cancer trial, which the 10-Q says is still being set. Third, quarterly operating cash use. Another quarter above $8.1 million would shorten a runway that is already about two months.
The company expects preliminary data from the randomized colorectal study by year-end.
What would change our mind: going concern language removed from a filing, a partner that pays for the registrational work, or a clear win for pelareorep in the randomized REO 033 study.